The capital raise and strong cash position reduce near-term financing risk and support value inflection via upcoming clinical data readouts. Traders should monitor warrant exercise activity, ELAINE-3 enrollment progress, and initiation of the ATH-1105 ALS trial as key catalysts.
Price Chart
Executive Summary
LeonaBio (LONA) reported its 2025 financial results and provided updates on its strategic transformation, including the acquisition of lasofoxifene for metastatic breast cancer and a $90 million private placement with potential for $146 million in additional capital via warrants. The company is advancing lasofoxifene into late-stage trials and preparing for a Phase 2 ALS study with ATH-1105, while significantly improving its cash position despite a wider net loss driven by one-time R&D acquisition costs.
Key Financial Metrics
Key Facts
- Acquired global rights (ex-Asia/Middle East) to lasofoxifene, a Phase 3 SERM for ESR1-mutated metastatic breast cancer, from Sermonix Pharmaceuticals.
- Raised $90 million in gross proceeds via private placement, with cash-exercisable warrants potentially adding $146 million in future capital.
- Cash, cash equivalents, and investments increased to $88.3 million as of December 31, 2025, up from $51.3 million in 2024.
- Net loss widened to $105.6 million in 2025 from $96.9 million in 2024, primarily due to $68.1 million in acquired in-process R&D costs.
- R&D expenses rose to $85.6 million (from $70.7M) due to lasofoxifene acquisition; G&A decreased to $16.7M (from $26.1M) due to cost efficiencies.
- Phase 3 ELAINE-3 trial enrollment expected to complete in Q4 2026, with topline data anticipated in H2 2027.
- Phase 2 proof-of-concept trial for ATH-1105 in ALS patients on track to initiate in H2 2026.
Financial Impact
Cash position increased by $37 million year-over-year to $88.3 million, despite $45.7 million in net cash used in operations. The $90 million financing (plus $146M potential from warrants) provides runway to fund key clinical milestones.
Risk Factors
- Clinical trial delays or failure to meet endpoints, particularly in the Phase 3 ELAINE-3 study.
- Dilution risk if warrants are exercised, potentially increasing share count significantly.
- High net loss and continued cash burn could pressure valuation if milestones are missed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263468 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D/A | $4.79 | awaiting T+60 | — | $4.76 (−0.63%) |
May 11, 2026 24w ago | DEFA14A | $10.17 $7.81 | ▼ −23.21% | ▼ −27.59% | $4.76 (−53.20%) |
May 7, 2026 24w ago | 3 | $10.04 $7.66 | ▼ −23.71% | ▼ −28.54% | $4.76 (−52.59%) |
Apr 23, 2026 26w ago | Press Release | $8.33 $7.98 | ▼ −4.20% | ▼ −9.28% | $4.76 (−42.86%) |
Mar 26, 2026 30w ago | Press Release | $8.97 $8.41 | ▼ −6.24% | ▼ −22.31% | $4.76 (−46.93%) |
Mar 4, 2026 33w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.76 (−20.40%) |
Mar 4, 2026 33w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.76 (−20.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers